Drug Profile
V 0191
Alternative Names: V-0191Latest Information Update: 25 Aug 2015
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Antidementias
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mild cognitive impairment
Most Recent Events
- 25 Aug 2015 Discontinued - Phase-II for Mild cognitive impairment in Austria, Belgium, Finland, France and Spain (PO)